Phreesia, Inc. (NYSE:PHR) Short Interest Update

Phreesia, Inc. (NYSE:PHR) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 4,404,667 shares, an increase of 21.0% from the February 26th total of 3,639,021 shares. Approximately 7.7% of the company’s stock are short sold. Based on an average trading volume of 1,474,342 shares, the short-interest ratio is currently 3.0 days.

Phreesia Trading Up 3.3%

Shares of Phreesia stock opened at $8.66 on Wednesday. The firm has a market cap of $521.99 million, a PE ratio of 283.53 and a beta of 0.67. Phreesia has a 1 year low of $7.77 and a 1 year high of $32.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. The stock has a fifty day moving average price of $12.36 and a 200-day moving average price of $17.57.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The company had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. During the same period last year, the firm posted ($0.11) earnings per share. Phreesia’s quarterly revenue was up 15.9% compared to the same quarter last year. Equities research analysts anticipate that Phreesia will post -1.1 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PHR shares. Canaccord Genuity Group lowered their price objective on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC lowered their target price on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday. Citizens Jmp reaffirmed a “market perform” rating on shares of Phreesia in a research report on Wednesday. Robert W. Baird reissued a “neutral” rating and set a $10.00 price objective (down from $25.00) on shares of Phreesia in a report on Tuesday. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $16.00 price objective (down from $24.00) on shares of Phreesia in a research note on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Insider Transactions at Phreesia

In other Phreesia news, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $107,452.17. Following the completion of the sale, the insider owned 834,632 shares of the company’s stock, valued at approximately $14,197,090.32. This trade represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Linetsky sold 6,106 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $103,863.06. Following the sale, the insider owned 231,723 shares of the company’s stock, valued at approximately $3,941,608.23. This represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 70,358 shares of company stock worth $1,123,569 in the last three months. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of hedge funds have recently modified their holdings of the stock. Granahan Investment Management LLC boosted its holdings in Phreesia by 73.8% in the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after buying an additional 1,018,987 shares during the period. Prosight Management LP bought a new position in shares of Phreesia in the fourth quarter worth $16,533,000. Millennium Management LLC boosted its holdings in shares of Phreesia by 730.7% in the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after acquiring an additional 936,033 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Phreesia in the fourth quarter valued at $15,213,000. Finally, Greenhouse Funds LLLP grew its position in shares of Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after purchasing an additional 557,265 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Company reported solid top‑line growth and improved cash flow: FYQ4 revenue rose ~15.9% to $127.1M and management highlighted positive GAAP net income, >$100M adjusted EBITDA and strong free cash flow — constructive fundamentals that could support a recovery once visibility improves. BusinessWire: Q4 results
• Positive Sentiment: Some sell‑side firms remain constructive on a longer horizon: Stephens kept an overweight stance (though cut its target to $20), indicating some analysts still see meaningful upside from current levels. Benzinga: Stephens lowers target
• Neutral Sentiment: Citizens JMP reaffirmed a “market perform” rating — a steady but non‑committal stance amid the guidance uncertainty. (No link provided in the bulletin.)
• Neutral Sentiment: Multiple firms reaffirmed neutral/hold ratings but cut targets (JPMorgan, Robert W. Baird, Citigroup, Truist) — these keep the stock in a wait‑and‑see category while reflecting lower near‑term expectations. Finviz: analyst notes
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility from pharmaceutical clients and weaker second‑half commitments — the guidance cut is the primary driver of today’s selloff. Benzinga: guidance cut
• Negative Sentiment: Earnings confusion and a reported quarterly EPS miss (MarketBeat: $0.02 vs. $0.07 consensus) added to negative sentiment even though revenue roughly met expectations — the mixed print amplified concerns about near‑term growth. MarketBeat: earnings summary
• Negative Sentiment: Broad analyst reaction: several firms slashed price targets and some pulled or downgraded recommendations, producing downward pressure and headlines like “plunges” and “we’re pulling our recommendation.” That wave of downgrades magnified the selloff. MSN: recommendation pulled

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.